Yun H, et al. Do Patients with Moderate or High Disease Activity Escalate RA Therapy According to Treat-to-Target Principles? Results from the ACR’s RISE Registry. ACR 2018, abstract 2856.
Veiligheidsprofiel baricitinib op lange termijn bij patiënten met actieve RA
nov 2021 | RA